OncoZenge AB Partners with UCLA to Enhance Patient Engagement in Pain Management Research
OncoZenge AB, a pharmaceutical company renowned for its innovative approaches to oral pain relief, recently announced a significant collaboration with the University of California, Los Angeles (UCLA). This partnership focuses on a patient engagement study centered around BupiZenge™, an experimental lozenge designed for managing oral mucositis pain, which is a common side effect of cancer treatments such as chemotherapy and radiation therapy.
The primary goal of this collaboration is to gain deeper insights into the unmet medical needs faced by patients suffering from oral mucositis. By leveraging UCLA's extensive expertise in oncology and patient care, OncoZenge aims to gather essential data to inform the clinical development of BupiZenge™ and potentially advance toward an Investigational New Drug (IND) application in the United States.
Stian Kildal, CEO of OncoZenge, expressed enthusiasm for the collaboration, highlighting UCLA’s stature in cancer research as a key benefit in understanding patient experiences. Kildal stated, "This partnership not only enhances our grasp of patients' needs through the engagement study but also helps us navigate the complex regulatory landscape toward a potential IND filing. Our goal is to make BupiZenge™ available for patients in the US market."
Robert K. Chin, MD, PhD, a radiation oncologist at UCLA Health, emphasized the debilitating nature of oral mucositis for many cancer patients undergoing treatment. He pointed out that collaborating with OncoZenge allows for a more profound exploration of patient concerns and the potential for innovative solutions like BupiZenge™. This partnership could greatly benefit future advancements in clinical treatment in the United States.
The study will focus on gathering patient feedback and experiences, which will provide OncoZenge with valuable insights to refine BupiZenge™ as a treatment option. BupiZenge™ is a non-opioid lozenge that offers localized and long-lasting pain relief specifically targeting oral pain caused by cancer therapies. This unique formulation aims to fill the gap in current care options available for managing severe oral pain, providing a safer alternative to systemic opioids which have significant side effects and risks associated with their use.
OncoZenge's collaboration with UCLA reflects its commitment to advancing BupiZenge™ on a global scale. While the company is already gearing up for Phase III trials in Europe, this new initiative reinforces its focus on patient-centered research and innovation in pain management.
The partnership also underscores a broader trend in pharmaceutical development, where patient engagement is increasingly recognized as crucial for creating effective treatment options. As the project unfolds, both OncoZenge and UCLA will likely continue to work closely to ensure that the voices of patients are not only heard but also integrated into the clinical development processes.
As BupiZenge™ progresses through its development phases, the emphasis on real-world patient insights may very well reshape the narrative surrounding pain management therapeutics in oncology. With the collaboration set in motion, OncoZenge and UCLA are poised to make significant contributions to improving the quality of life for patients battling with oral mucositis.
The primary goal of this collaboration is to gain deeper insights into the unmet medical needs faced by patients suffering from oral mucositis. By leveraging UCLA's extensive expertise in oncology and patient care, OncoZenge aims to gather essential data to inform the clinical development of BupiZenge™ and potentially advance toward an Investigational New Drug (IND) application in the United States.
Stian Kildal, CEO of OncoZenge, expressed enthusiasm for the collaboration, highlighting UCLA’s stature in cancer research as a key benefit in understanding patient experiences. Kildal stated, "This partnership not only enhances our grasp of patients' needs through the engagement study but also helps us navigate the complex regulatory landscape toward a potential IND filing. Our goal is to make BupiZenge™ available for patients in the US market."
Robert K. Chin, MD, PhD, a radiation oncologist at UCLA Health, emphasized the debilitating nature of oral mucositis for many cancer patients undergoing treatment. He pointed out that collaborating with OncoZenge allows for a more profound exploration of patient concerns and the potential for innovative solutions like BupiZenge™. This partnership could greatly benefit future advancements in clinical treatment in the United States.
The study will focus on gathering patient feedback and experiences, which will provide OncoZenge with valuable insights to refine BupiZenge™ as a treatment option. BupiZenge™ is a non-opioid lozenge that offers localized and long-lasting pain relief specifically targeting oral pain caused by cancer therapies. This unique formulation aims to fill the gap in current care options available for managing severe oral pain, providing a safer alternative to systemic opioids which have significant side effects and risks associated with their use.
OncoZenge's collaboration with UCLA reflects its commitment to advancing BupiZenge™ on a global scale. While the company is already gearing up for Phase III trials in Europe, this new initiative reinforces its focus on patient-centered research and innovation in pain management.
The partnership also underscores a broader trend in pharmaceutical development, where patient engagement is increasingly recognized as crucial for creating effective treatment options. As the project unfolds, both OncoZenge and UCLA will likely continue to work closely to ensure that the voices of patients are not only heard but also integrated into the clinical development processes.
As BupiZenge™ progresses through its development phases, the emphasis on real-world patient insights may very well reshape the narrative surrounding pain management therapeutics in oncology. With the collaboration set in motion, OncoZenge and UCLA are poised to make significant contributions to improving the quality of life for patients battling with oral mucositis.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.